Nurix Therapeutics Inc. | Small-cap | Healthcare
$8.44
-2.65%
| Nurix Therapeutics Stock Comparison:
Nurix Therapeutics vs VertexNurix Therapeutics vs AlnylamNurix Therapeutics vs RecursionNurix Therapeutics vs AdaptiveNurix Therapeutics vs Harmony BiosciencesNurix Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: May 2025

Income Metrics

Revenue 44.1M
Operating Income -48.3M -109.68%
Net Income -43.5M -98.66%
EPS (Diluted) $-0.52

Balance Sheet Metrics

Total Assets 615.0M
Total Liabilities 134.1M
Shareholders Equity 480.9M
Debt to Equity 0.28

Cash Flow Metrics

Operating Cash Flow -58.2M
Free Cash Flow -64.6M

Revenue & Profitability Trend

Nurix Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i54.5M77.0M38.6M29.8M17.8M
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i221.6M189.1M184.5M116.4M66.5M
Selling, General & Administrative i45.9M42.9M38.0M31.2M16.3M
Other Operating Expenses i-----
Total Operating Expenses i267.6M232.0M222.5M147.6M82.8M
Operating Income i-213.0M-155.1M-183.9M-117.9M-65.0M
Operating Margin % i-390.5%-201.4%-476.0%-396.3%-364.7%
Non-Operating Items
Interest Income i19.7M11.1M3.5M823.0K1.2M
Interest Expense i-----
Other Non-Operating Income-----
Pre-tax Income i-193.3M-143.9M-180.4M-117.1M-63.8M
Income Tax i270.0K00131.0K-20.5M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-193.6M-143.9M-180.4M-117.2M-43.2M
Net Margin % i-354.9%-187.0%-466.9%-393.9%-242.7%
Key Metrics
EBITDA i-196.6M-141.4M-173.1M-111.8M-62.8M
EPS (Basic) i$-2.88$-2.65$-3.71$-2.73$-2.76
EPS (Diluted) i$-2.88$-2.65$-3.71$-2.73$-2.76
Basic Shares Outstanding i6712026654337901486079904289538315673424
Diluted Shares Outstanding i6712026654337901486079904289538315673424

Income Statement Trend

Nurix Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i110.0M54.6M64.5M80.5M119.4M
Short-term Investments i499.6M233.3M244.7M215.2M161.8M
Accounts Receivable i--06.0M0
Inventory i-----
Other Current Assets9.8M7.6M9.3M9.2M5.9M
Total Current Assets i619.4M295.5M318.4M311.1M298.4M
Non-Current Assets
Property, Plant & Equipment i67.2M63.4M38.7M32.3M14.1M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets4.1M4.7M4.9M3.1M347.0K
Total Non-Current Assets i50.0M60.1M98.3M165.7M97.9M
Total Assets i669.3M355.6M416.8M476.8M396.3M
Liabilities
Current Liabilities
Accounts Payable i11.5M6.4M5.1M6.6M3.4M
Short-term Debt i8.0M7.5M5.5M3.8M-
Current Portion of Long-term Debt-----
Other Current Liabilities2.3M751.0K1.5M659.0K700.0K
Total Current Liabilities i95.9M87.0M70.7M66.3M44.5M
Non-Current Liabilities
Long-term Debt i20.3M23.1M6.4M9.2M0
Deferred Tax Liabilities i-----
Other Non-Current Liabilities----850.0K
Total Non-Current Liabilities i46.5M68.1M42.4M68.2M61.5M
Total Liabilities i142.4M155.1M113.1M134.5M106.1M
Equity
Common Stock i76.0K49.0K47.0K45.0K39.0K
Retained Earnings i-738.8M-545.2M-401.3M-220.9M-103.7M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i527.0M200.5M303.7M342.3M290.3M
Key Metrics
Total Debt i28.3M30.6M12.0M13.0M0
Working Capital i523.5M208.5M247.8M244.9M253.9M

Balance Sheet Composition

Nurix Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-193.6M-143.9M-180.4M-117.2M-43.2M
Depreciation & Amortization i16.4M13.7M10.8M6.1M2.2M
Stock-Based Compensation i33.9M33.7M28.1M15.8M4.3M
Working Capital Changes i-29.8M14.9M-25.4M8.3M38.1M
Operating Cash Flow i-172.7M-81.8M-166.6M-87.0M1.3M
Investing Activities
Capital Expenditures i-9.3M-8.4M-12.2M-5.7M-4.6M
Acquisitions i-----
Investment Purchases i-708.0M-246.3M-239.4M-348.5M-275.2M
Investment Sales i459.5M323.0M278.8M245.9M25.4M
Investing Cash Flow i-257.7M68.3M27.2M-108.3M-254.4M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i478.5M0114.2M150.2M338.1M
Free Cash Flow i-181.9M-89.8M-172.1M-90.0M-4.6M
Net Change in Cash i48.1M-13.5M-25.3M-45.1M85.0M

Cash Flow Trend

Nurix Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -3.11
Forward P/E -3.31
Price to Book 1.57
Price to Sales 7.96
PEG Ratio 0.12

Profitability Ratios

Profit Margin -234.57%
Operating Margin -109.68%
Return on Equity -50.67%
Return on Assets -26.13%

Financial Health

Current Ratio 6.82
Debt to Equity 11.60
Beta 2.10

Per Share Data

EPS (TTM) $-2.60
Book Value per Share $5.86
Revenue per Share $1.11

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
nrix684.2M-3.111.57-50.67%-234.57%11.60
Vertex 101.2B28.085.8922.77%31.86%8.89
Alnylam 60.4B-211.56241.63-257.83%-12.96%1,093.31
Recursion 2.1B-2.862.27-86.34%22.65%9.58
Adaptive 1.9B-11.6810.68-57.60%-59.07%121.39
Harmony Biosciences 1.9B10.332.3827.58%23.42%22.43

Financial data is updated regularly. All figures are in the company's reporting currency.